: iStockAnalyst.com Symbols Feed

Small-Cap Stocks Battling Brain Cancer

Tue, 08 Sep 2009 00:02:23 GMT

Each year nearly 20,000 people in the U.S. are diagnosed with primary brain cancers (with a similar number in Europe), according to NCI/NIH statistics, with Schering-Plough's (NYSE:SGP) Temodar (temozolomide or TMZ is classified as a DNA-methylating chemotherapy drug) given to nearly every patient with a diagnosis of GBM (the most common and aggressive form of brain cancer).[More...]

The Clock Is Ticking On Micromet (MITI)

Tue, 25 Aug 2009 00:05:20 GMT

Earlier this month, Micromet (MITI) concluded an impressive public offering of $75M, approximately 20% of the company’s market cap. The offering illustrates the transformation the company has undergone from an anonymous biotech play into a recognized industry leader. This is also echoed by the growing attention from Wall St. When I first wrote about Micromet in 2007, the company was covered by a single analyst,[More...]

Biotech Portfolio Updates – Incyte (NASDAQ: INCY)

Tue, 11 Aug 2009 13:53:37 GMT

A drug with an almost certain approval and immediate sales potential of hundreds of millions of dollars is an asset very few biotech companies possess. In that sense, Incyte (INCY), which is developing a breakthrough drug for blood[More...]

Technically Significant Day As Indices Make Large Gains

Tue, 02 Jun 2009 00:30:50 GMT

The indices started the week with a bang and ended with big gains on the day. The session started out with a big gap to the upside. They ran very sharply higher and hard early on, eased into a lower angle of ascent, but continued higher all morning, backed and filled mid-day, and reached their mid-day and session peaks with about 3 hours to go. Then they rolled over to do a serious test in late afternoon that held at 1470 NDX and 940 SPX. The last hour saw a sharp snapback towards the session highs, and then they pulled back a little into the close. Net on the day the Dow was up 221.11 at 8721.44, the S&P 500 up 23.73 at 942.87, and the Nasdaq 100 up 41.55 at 1477.12. The Philadelphia Semiconductor Index (SOXX) had a monster day, up 14.40, nearly 5 percent, at 285.71. Advance-declines were 5 to 1 positive on New York and about[More...]

Top Picks For ASCO 2009

Tue, 26 May 2009 11:44:28 GMT

The ASCO annual meeting, one of the most important events in the pharmaceutical industry will take place in Orlando next weekend. With over 4,000 abstracts to be presented this year, separating the wheat from the chaff is difficult, but below is an incomp[More...]

Micromet (Nasdaq: MITI) – More Reasons For Optimism

Sun, 10 May 2009 17:03:16 GMT

Two weeks ago, Micromet (MITI) hosted its annual R&D day, where it discussed plans for 2009 and beyond.[More...]

Biotech Portfolio Updates - Rigel Is Still On Track, Pfizer May Have Found Its Next Blockbuster

Fri, 09 Jan 2009 14:06:00 GMT

In the pharmaceutical industry, 2008 will probably be marked by the big pharmas’ insatiable appetite for new drugs. Threatened by fierce generic competition, the pharmaceutical giants were not only eager to pay generous acquisition premiums for marketed[More...]

Top 40 Rated Emerging Bio-Pharma Stocks

Mon, 22 Dec 2008 16:22:00 GMT

The accompanying table (click to enlarge) highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators (ETFI) Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return. The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq[More...]

Immunogen and Exelixis Defy the Myth of Recession

Sun, 21 Dec 2008 01:09:00 GMT

: iStockAnalyst.com Symbols Feed

Small-Cap Stocks Battling Brain Cancer

The Clock Is Ticking On Micromet (MITI)

Biotech Portfolio Updates – Incyte (NASDAQ: INCY)

Technically Significant Day As Indices Make Large Gains

Top Picks For ASCO 2009

Micromet (Nasdaq: MITI) – More Reasons For Optimism

Biotech Portfolio Updates - Rigel Is Still On Track, Pfizer May Have Found Its Next Blockbuster

Top 40 Rated Emerging Bio-Pharma Stocks

Immunogen and Exelixis Defy the Myth of Recession

6 Hot Stocks To Watch: Market Is This Really The Best You’ve Got ?

Revlon, General Motors, Palm are big movers

Big Deals to Reshape Bay Area Biotech

Big Deals Reshape Bay Area Biotech Industry

Mead Johnson Sales Push 4q Profit

Plavix sales help Bristol-Myers swing to Q4 profit - Jan 27 2009 7:20PM

Plavix sales help Bristol-Myers swing to Q4 profit - Jan 27 2009 11:45AM

Exelixis Announces August 11 Webcast of Presentation at the Canaccord Adams 29th Annual Global Growth Conference

Exelixis Announces Second Quarter 2009 Financial Results

Exelixis Announces July 30 Webcast of Its Second Quarter 2009 Financial Results Conference Call

Exelixis Announces June 24 Webcast of Presentation at the Piper Jaffray Europe Conference

Exelixis Announces June 9 Webcast of Presentation at the Goldman Sachs Thirtieth Annual Healthcare Conference

Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL765, a Dual Inhibitor of PI3K and mTOR

Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL147, a Selective Inhibitor of PI3K

Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma Multiforme

Exelixis Reports Encouraging Phase 1 Data to Be Presented at ASCO for XL228, a Multi-Targeted Inhibitor of Key Cancer Signaling Kinases

Exelixis and Sanofi-aventis Sign Global License Agreement for XL147 & XL765 and Launch Broad Collaboration for Discovery of PI3K Inhibitors

Form 4 Heller Frances K For: Nov 02 (10K)

Form 4 Lamb Peter For: Aug 04 (10K)

Form 4 RIVERA LUPE M For: Aug 04 (10K)

Form 4 Schwab Gisela For: Jun 03 (10K)

Form 4 Heller Frances K For: Jun 03 (10K)

Form 4 Garber Alan M For: May 14 (10K)

Form 4 WYSZOMIERSKI JACK L For: May 14 (10K)

Form 4 MCCORMICK FRANK For: May 14 (10K)

Form 4 FELDBAUM CARL B For: May 14 (10K)

Form 4 POSTE GEORGE For: May 14 (10K)